The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 13, 2021
Filed:
Aug. 27, 2019
Applicant:
Pharmakea, Inc., San Diego, CA (US);
Inventors:
Martin W. Rowbottom, San Diego, CA (US);
John Howard Hutchinson, San Diego, CA (US);
Assignee:
PHARMAKEA, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/47 (2006.01); A61K 31/4709 (2006.01); C07D 413/04 (2006.01); C07D 401/12 (2006.01); A61K 9/06 (2006.01); A61K 9/20 (2006.01); C07D 401/04 (2006.01); A61K 9/14 (2006.01); C07D 401/06 (2006.01); C07D 215/48 (2006.01); C07D 215/233 (2006.01); C07D 417/04 (2006.01); A61K 47/38 (2006.01); C07D 215/38 (2006.01); A61K 9/00 (2006.01); A61K 31/4725 (2006.01); A61P 7/04 (2006.01); A61P 25/00 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 9/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4709 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/146 (2013.01); A61K 9/2054 (2013.01); A61K 31/47 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 47/38 (2013.01); A61P 7/04 (2018.01); A61P 25/00 (2018.01); C07D 215/233 (2013.01); C07D 215/38 (2013.01); C07D 215/48 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01);
Abstract
Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.